[Radiofrequency ablation for the treatment of benign and malign nodules of endocrine organs (thyroid gland and adrenal gland]
Fischer S, Zechmeister-Koss I
Record ID 32012000774
German
Authors' objectives:
Radiofrequency ablation (RFA) is a relatively new, minimally-invasive ablation method that destroys tumors by local application of heat. This systematic review evaluates the following indications of RFA for the treatment of benign and malignant lesions of endocrine organs: benign thyroid nodules and throid cancer as well as adrenocortical adenomas and adrenal metastases.
Authors' recommendations:
According to GRADE, the quality of evidence is very low due to the uncontrolled study design of the included case series. Overall, the available evidence is insufficient to assess the efficacy and safety of RFA compared to the respective standard therapy for the treatment of benign and malignant lesions of endocrine organs. Currently, the inclusion into the hospital benefit catalogue is not recommended.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://eprints.hta.lbg.ac.at/960/1/DSD_56.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Adrenal Gland Neoplasms
- Catheter Ablation
- Endocrine Gland Neoplasms
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.